134 related articles for article (PubMed ID: 37328659)
21. Germline pathogenic
Witkowski L; Nichols KE; Jongmans M; van Engelen N; de Krijger RR; Herrera-Mullar J; Tytgat L; Bahrami A; Mar Fan H; Davidson AL; Robertson T; Anderson M; Hasselblatt M; Plon SE; Foulkes WD
J Med Genet; 2023 Oct; 60(10):987-992. PubMed ID: 36813544
[TBL] [Abstract][Full Text] [Related]
22. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
Kloosterhof NK; Bralten LB; Dubbink HJ; French PJ; van den Bent MJ
Lancet Oncol; 2011 Jan; 12(1):83-91. PubMed ID: 20615753
[TBL] [Abstract][Full Text] [Related]
23. Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis.
Phan K; Ng W; Lu VM; McDonald KL; Fairhall J; Reddy R; Wilson P
World Neurosurg; 2018 Mar; 111():e539-e545. PubMed ID: 29288860
[TBL] [Abstract][Full Text] [Related]
24. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
[TBL] [Abstract][Full Text] [Related]
25. The evolving genomic landscape of recurrent gliomas.
Ampie L; Kusne Y; Sanai N
World Neurosurg; 2015 May; 83(5):722-3. PubMed ID: 25765925
[No Abstract] [Full Text] [Related]
26. Identification of an Arg35X mutation in the PDCD10 gene in a patient with cerebral and multiple spinal cavernous malformations.
Lee ST; Choi KW; Yeo HT; Kim JW; Ki CS; Cho YD
J Neurol Sci; 2008 Apr; 267(1-2):177-81. PubMed ID: 18035376
[TBL] [Abstract][Full Text] [Related]
27. Surveying genetic variants and molecular phylogeny of cerebral cavernous malformation gene, CCM3/PDCD10.
Kumar A; Bhandari A; Goswami C
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):98-106. PubMed ID: 25451273
[TBL] [Abstract][Full Text] [Related]
28. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
29. Expanding the spectrum of IDH1 mutations in gliomas.
Gupta R; Flanagan S; Li CC; Lee M; Shivalingham B; Maleki S; Wheeler HR; Buckland ME
Mod Pathol; 2013 May; 26(5):619-25. PubMed ID: 23307057
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
31. Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.
Odia Y; Varma H; Tsankova NM
Clin Neuropathol; 2015; 34(5):282-7. PubMed ID: 25907263
[TBL] [Abstract][Full Text] [Related]
32. Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancer.
Herold N; Schmolling J; Ernst C; Ataseven B; Blümcke B; Schömig-Markiefka B; Heikaus S; Göhring UJ; Engel C; Lampe B; Rhiem K; Harter P; Hauke J; Schmutzler RK; Hahnen E
Cancer Med; 2023 Jul; 12(14):15256-15260. PubMed ID: 37345881
[TBL] [Abstract][Full Text] [Related]
33. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
34. Undifferentiated colonic neoplasm with SMARCA4 germline gene mutation and loss of SMARCA4 protein expression: a case report and literature review.
Duan H; Gao W; Wang L; Cao F; Teng L
Diagn Pathol; 2021 Apr; 16(1):30. PubMed ID: 33836796
[TBL] [Abstract][Full Text] [Related]
35. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.
Liu XY; Gerges N; Korshunov A; Sabha N; Khuong-Quang DA; Fontebasso AM; Fleming A; Hadjadj D; Schwartzentruber J; Majewski J; Dong Z; Siegel P; Albrecht S; Croul S; Jones DT; Kool M; Tonjes M; Reifenberger G; Faury D; Zadeh G; Pfister S; Jabado N
Acta Neuropathol; 2012 Nov; 124(5):615-25. PubMed ID: 22886134
[TBL] [Abstract][Full Text] [Related]
36. Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood.
Huse JT
Surg Pathol Clin; 2016 Sep; 9(3):379-90. PubMed ID: 27523967
[TBL] [Abstract][Full Text] [Related]
37. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.
Yu J; Shi Z; Lian Y; Li Z; Liu T; Gao Y; Wang Y; Chen L; Mao Y
Eur Radiol; 2017 Aug; 27(8):3509-3522. PubMed ID: 28004160
[TBL] [Abstract][Full Text] [Related]
38. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of gliomas peritumoral diffusion and prediction of IDH1 mutation by IVIM-DWI.
Gu T; Yang T; Huang J; Yu J; Ying H; Xiao X
Aging (Albany NY); 2021 Mar; 13(7):9948-9959. PubMed ID: 33795525
[TBL] [Abstract][Full Text] [Related]
40. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.
Liu T; Cheng G; Kang X; Xi Y; Zhu Y; Wang K; Sun C; Ye J; Li P; Yin H
Neuroradiology; 2018 Jul; 60(7):693-702. PubMed ID: 29777252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
